Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

anaplastic astrocytoma - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

anaplastic astrocytoma

MONDO:0016684

Also known as:astrocytoma, anaplastic, malignantgrade III astrocytic neoplasmgrade III astrocytic tumor

Find Clinical TrialsTrials

Overview

Anaplastic astrocytoma is a rare, high-grade, malignant glial tumor, histologically characterized by abundance of pleomorphic astrocytes and multiple mitotic figures, often associated with diffuse infiltration of the surrounding tissue, considerable edema and mass effect and involvement of the contralateral brain. Depending on the primary localization of the tumor, patients can present with signs of raised intracranial pressure (headache, vomiting, papilledema), seizures, progressive neurological deficits, and/or behavioral changes. The tumor is most commonly localized in the frontal and temporal lobes, brain stem and spinal cord.

Treatments1 FDA approved

Clinical Trials33 registered · 15 recruiting

Diagnosis

Biomarker and diagnostic research for anaplastic astrocytoma has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for anaplastic astrocytoma, including TEMOZOLOMIDE (TEMODAR, approved 2009). An additional 1 compound holds orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

33 clinical trials registered, 15 recruiting. Interventions under study include drug therapy, procedural interventions, other interventions, and biologic therapy. Pipeline includes 1 PHASE4, 8 PHASE2, 16 PHASE1. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT02800486](https://clinicaltrials.gov/study/NCT02800486)

Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 3:03 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:251589

GARD

Genetic and Rare Diseases Info Center

GARD:5860

Questions for Your Care Team

→What are the benefits and potential side effects of TEMODAR for managing anaplastic astrocytoma?
→Are any of the 33 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B)	Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B)	Peregrine Pharmaceuticals, Inc.	1999	—	Designated

Research Type	Count	% of Total
Laboratory research	34	27%
Research summaries	24	19%
Clinical study results	20	16%
Disease patterns and progression	16	13%
Testing and diagnosis research	15	12%
Patient case studies	12	9%
New treatment approaches	7	5%

Kisho

anaplastic astrocytoma

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

anaplastic astrocytoma

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications